Informed decision‐making in hereditary angioedema prophylaxis

When is prophylaxis for hereditary angioedema necessary?

OBJECTIVE To determine when newer agents, such as C1 esterase inhibitor protein (C1-INH), should be considered as prophylaxis to decrease hereditary angioedema (HAE) attacks as an alternative to androgens, which have significant adverse events. DATA SOURCES A literature review (PubMed, Google, and Ovid), guideline review, expert panel meeting, and group discussion were performed to decide whe...

Inhibiting Plasma Kallikrein for Hereditary Angioedema Prophylaxis.

BACKGROUND Hereditary angioedema with C1 inhibitor deficiency is characterized by recurrent, unpredictable swelling episodes caused by uncontrolled plasma kallikrein generation and excessive bradykinin release resulting from cleavage of high-molecular-weight kininogen. Lanadelumab (DX-2930) is a new kallikrein inhibitor with the potential for prophylactic treatment of hereditary angioedema with...

Long-term Prophylaxis in Hereditary Angioedema: a Systematic Review

Medicaid Consumers and Informed Decisionmaking

In 2006, Florida's Medicaid reform required some Medicaid consumers to enroll in health plans that differed in terms of cost-sharing requirements and benefit limitations. In focus groups we found enthusiasm among Medicaid consumers for having choices among health plans; however, enthusiasm did not translate into comparison shopping for health plans. Survey findings suggested that Medicaid consu...

Hereditary Angioedema

Copyright © 2008 Massachusetts Medical Society. A 19-year-old woman presents to the emergency department with light-headedness, severe abdominal pain, and intractable nausea and vomiting that began 12 hours earlier. The patient reports previous episodes of abdominal pain and swelling of her hands and feet that have been attributed possibly to food allergies, which have recently become more freq...